The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients
Article in Drugs & Therapy Perspectives (December 2023)
The most recent citing publications are shown below. View all 8 publications that cite this research output on Dimensions.
Article in Drugs & Therapy Perspectives (December 2023)
Article in Research in Social and Administrative Pharmacy (November 2021)
Article in Targeted Oncology (November 2019)